REGN Investor Alert: Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud

Regeneron executives told investors Fianlimab + Libtayo was one of their “potential blockbusters" just weeks before the drug combination’s Phase 3 melanoma trial failed its primary endpoint against Keytruda.

NEW YORK--(BUSINESS WIRE)--Regeneron Pharmaceuticals (NASDAQ: REGN) shares dropped sharply after the Company disclosed on May 16, 2026, that its Phase 3 trial of fianlimab plus Libtayo in first-line metastatic melanoma failed to meet its primary endpoint versus Merck's Keytruda. Shareholders who lost money on REGN are encouraged to submit their information here. You may also contact Joseph E. Levi, Esq. via email at [e-mail] or by telephone at [phone].

During the Q1 2026 earnings call on April 29, 2026, Regeneron executives stated that the Phase 3 melanoma study "remains on track with results expected later in the second quarter of this year." Chief Science Officer George D. Yancopoulos highlighted “fianlimab Libtayo” as one among the company’s “potential blockbusters,” noting it was “hard to think of a more exciting pipeline in the entire industry.” Less than three weeks later, Regeneron announced the phase 3 trial for the drug combination had failed.

The investigation concerns whether Regeneron's statements regarding the fianlimab trial's progress adequately reflected the information available to management at the time they were made. If you purchased Regeneron shares and suffered a loss, click here to discuss your legal rights. You may also contact Joseph E. Levi, Esq. via email at [e-mail] or by telephone at [phone].

WHY LEVI & KORSINSKY -- Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors.

Frequently Asked Questions About the REGN Investigation

Q: Who is conducting the REGN investigation? A: Levi & Korsinsky, LLP is investigating potential securities law violations on behalf of investors who purchased REGN securities. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered hundreds of millions of dollars for aggrieved investors.

Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Regeneron made materially false or misleading statements regarding the potential, progress, and prospects of its Phase 3 fianlimab melanoma trial. When the trial failure was revealed, the stock price declined sharply.

Q: Who is eligible to participate in the REGN investigation? A: Investors who purchased REGN stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: What do REGN investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [e-mail] or [phone]. No immediate action is required to remain eligible to participate in the investigation.

Q: What if I already sold my REGN shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought REGN and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate? A: Nothing. Securities investigations are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions.